Targeting the tumor microenvironment: from understanding pathways to effective clinical trials.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Cancer Research

• Publication date

  2013-08-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-13-0661PMID 23913938PMCID PMC3815577
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial (vol 13, pg 549, 2012)

  2013cited by this paper
• TGF beta signaling and its role in glioma pathogenesis.

  2013cited by this paper
• Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?

  2013cited by this paper
• The development of denosumab for the treatment of diseases of bone loss and cancer‐induced bone destruction

  2012cited by this paper
• The diverse and complex roles of NF-κB subunits in cancer

  2012cited by this paper
• Benefit-Risk Assessment of Bevacizumab in the Treatment of Breast Cancer

  2012cited by this paper
• Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.

  2012cited by this paper
• Proteasome inhibitors.

  2012cited by this paper
• Macrophage plasticity and polarization: in vivo veritas.

  2012cited by this paper
• First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy.

  2012cited by this paper
• Accessories to the crime: functions of cells recruited to the tumor microenvironment.

  2012cited by this paper
• Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models

  2012cited by this paper
• Maximum-tolerated dose, optimum biologic dose, or optimum clinical value: dosing determination of cancer therapies.

  2012cited by this paper
• VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex.

  2012cited by this paper
• Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors.

  2012cited by this paper
• Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial

  2012cited by this paper
• A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients

  2011cited by this paper
• Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer.

  2011cited by this paper
• Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis.

  2011cited by this paper
• FDA pulls approval for avastin in breast cancer.

  2011cited by this paper
• Making molecular diagnostics ready for prime time.

  2011cited by this paper
• Cancer immunotherapy comes of age

  2011cited by this paper
• Targeting hypoxia in cancer therapy

  2011cited by this paper
• HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression

  2011cited by this paper
• A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma

  2011cited by this paper
• Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study.

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies

  2011cited by this paper
• Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis

  2011cited by this paper
• HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab

  2011cited by this paper
• Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer

  2011cited by this paper
• Efficacy and safety of concurrent chemoradiation with weekly cisplatin ± low-dose celecoxib in locally advanced undifferentiated nasopharyngeal carcinoma: a phase II-III clinical trial.

  2011cited by this paper
• Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

  2011cited by this paper
• Transforming growth factor-β in the gastrointestinal and hepatic tumor microenvironment.

  2011cited by this paper
• Future directions of bone-targeted therapy for metastatic breast cancer

  2010cited by this paper
• A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma

  2010cited by this paper
• A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer

  2010cited by this paper
• A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin αvβ3, ± dacarbazine in patients with stage IV metastatic melanoma

  2010cited by this paper
• Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm

  2010cited by this paper
• Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

  2010cited by this paper
• Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.

  2010cited by this paper
• Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study

  2010cited by this paper
• PDGF and vessel maturation.

  2010cited by this paper
• Macrophage diversity enhances tumor progression and metastasis.

  2010cited by this paper
• Therapeutic potential of JAK2 inhibitors.

  2009cited by this paper
• JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia

  2009cited by this paper
• Environment-mediated drug resistance: a major contributor to minimal residual disease

  2009cited by this paper
• A Phase I/II Study of Etanercept and Rituximab in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

  2009cited by this paper
• The cancer genome

  2009cited by this paper
• Resistance to targeted therapy in renal-cell carcinoma.

  2009cited by this paper
• STATs in cancer inflammation and immunity: a leading role for STAT3

  2009cited by this paper
• New, Long-term Insights from the Adenoma Prevention with Celecoxib Trial on a Promising but Troubled Class of Drugs

  2009cited by this paper
• Tirapazamine: a novel agent targeting hypoxic tumor cells.

  2009cited by this paper
• Molecular biology of bone metastasis.

  2008cited by this paper
• Hypoxia signalling through mTOR and the unfolded protein response in cancer

  2008cited by this paper
• Pathways Mediating Resistance to Vascular Endothelial Growth Factor–Targeted Therapy

  2008cited by this paper
• A Phase 1 Open-Label, Accelerated Dose-Escalation Study of the Hypoxia-Activated Prodrug AQ4N in Patients with Advanced Malignancies

  2008cited by this paper
• Role of platelet-derived growth factors in physiology and medicine.

  2008cited by this paper
• Modes of resistance to anti-angiogenic therapy

  2008influential reference
• TGFbeta in Cancer.

  2008cited by this paper
• Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.

  2008cited by this paper
• Hypoxia and metabolism: Hypoxia, DNA repair and genetic instability

  2008cited by this paper
• AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

  2007cited by this paper
• Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo.

  2007cited by this paper
• Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies.

  2007cited by this paper
• Inhibition of TGF-β2 with AP 12009 in Recurrent Malignant Gliomas: From Preclinical to Phase I/II Studies

  2007cited by this paper
• METASTASIS TO BONE : CAUSES , CONSEQUENCES AND THERAPEUTIC OPPORTUNITIES

  2007cited by this paper
• Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose.

  2007cited by this paper
• Simultaneous inhibition of COX-2 and 5-LOX activities augments growth arrest and death of premalignant and malignant human lung cell lines.

  2007cited by this paper
• A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model

  2006cited by this paper
• Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer

  2006cited by this paper
• Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer.

  2006cited by this paper
• Proteasome inhibitor bortezomib for the treatment of multiple myeloma

  2006cited by this paper
• Paradoxical roles of the immune system during cancer development

  2006cited by this paper
• TNF-alpha in promotion and progression of cancer.

  2006cited by this paper
• Microsomal prostaglandin E2 synthase‐1 in breast cancer: a potential target for therapy

  2006cited by this paper
• TNF-α in promotion and progression of cancer

  2006cited by this paper
• Angiogenesis as a therapeutic target

  2005cited by this paper
• NF-kappaB: linking inflammation and immunity to cancer development and progression.

  2005cited by this paper
• Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy

  2005cited by this paper
• Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer.

  2005cited by this paper
• Overexpression of 5-Lipoxygenase and Cyclooxygenase 2 in Hamster and Human Oral Cancer and Chemopreventive Effects of Zileuton and Celecoxib

  2005cited by this paper
• Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling

  2005cited by this paper
• Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.

  2005cited by this paper
• NF-κB functions as a tumour promoter in inflammation-associated cancer

  2004cited by this paper
• A Phase II Study of Etanercept (Enbrel), a Tumor Necrosis Factor α Inhibitor in Patients with Metastatic Breast Cancer

  2004cited by this paper
• Colony-Stimulating Factor-1 Blockade by Antisense Oligonucleotides and Small Interfering RNAs Suppresses Growth of Human Mammary Tumor Xenografts in Mice

  2004cited by this paper
• NF-kappaB functions as a tumour promoter in inflammation-associated cancer.

  2004cited by this paper
• A phase I surrogate endpoint study of SU6668 in patients with solid tumors

  2004cited by this paper
• Friends or foes — bipolar effects of the tumour stroma in cancer

  2004cited by this paper
• Epidermal growth factor receptor in tumor angiogenesis.

  2004cited by this paper
• The IKK NF-kappa B system: a treasure trove for drug development.

  2004cited by this paper
• Angiogenesis: Tumorigenesis and the angiogenic switch

  2003cited by this paper
• Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.

  2003cited by this paper
• Proteasome inhibitors.

  2002cited by this paper
• Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations

  2002cited by this paper
• Integrins: bidirectional, allosteric signaling machines.

  2002cited by this paper
• Colony-stimulating factor-1 antisense treatment suppresses growth of human tumor xenografts in mice.

  2002cited by this paper
• Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities

  2002cited by this paper
• Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?

  2002cited by this paper

• Roles of THBS2+ fibroblasts in malignant transformation of colorectal polyp to cancer.

  2026cites this paper
• Antibody-Nanoparticle Conjugates for Precision Targeting of Immunosuppressive Tumor Microenvironment.

  2026cites this paper
• A narrative review on tumor microenvironment in malignant tumors

  2025cites this paper
• Targeting the tumor microenvironment in triple-negative breast cancer: Biological insights and therapeutic opportunities.

  2025cites this paper
• Single-cell and spatial transcriptomics integration: new frontiers in tumor microenvironment and cellular communication

  2025cites this paper
• Advancements in Artificial Cell Preparation and Biomedical Applications

  2025cites this paper
• Downregulation of the CCK-B Receptor in Pancreatic Stellate Cells Blocks Molecular Proliferative Pathways and Increases Apoptosis to Decrease Pancreatic Cancer Growth In Vitro

  2025cites this paper
• Anti-ceramide antibody and sphingosine-1-phosphate as potential biomarkers of unresectable non-small cell lung cancer

  2025cites this paper
• Tumor microenvironment and immunotherapy: from bench to bedside

  2025influential citation
• Artemisinin derivatives maintain fibroblast normalization by acting on tumor-stroma interactions in oral tongue squamous cell carcinoma.

  2025cites this paper
• Harnessing glycolysis- and cholesterol synthesis-related genes for prognostic modeling in lung adenocarcinoma.

  2025cites this paper
• Recent advances in therapeutic use of transforming growth factor-beta inhibitors in cancer and fibrosis

  2025cites this paper
• Magnetized Cellular Robots for Precision Cytokine Delivery: A Novel Approach to Tumor-Targeted Therapy

  2025cites this paper
• 4-Methylumbelliferone, an Inhibitor of Hyaluronan Synthase, Prevents the Development of Oncological, Inflammatory, Degenerative, and Autoimmune Diseases

  2025cites this paper
• Biological role and potential significance of salivary IL6, IL8, IL1-RA and TNFα in oral squamous cell carcinoma and potentially malignant disorders

  2024cites this paper
• The S100 family is a prognostic biomarker and correlated with immune cell infiltration in pan-cancer

  2024cites this paper
• Bispecific aptamer-decorated and light-triggered nanoparticles targeting tumor and stromal cells in breast cancer derived organoids: implications for precision phototherapies

  2024cites this paper
• Impact of opioids and mu-opioid receptors on oncologic metastasis.

  2024cites this paper
• SERPINE1: Role in Cholangiocarcinoma Progression and a Therapeutic Target in the Desmoplastic Microenvironment

  2024cites this paper
• In Situ Cocktail Nanovaccine for Cancer Immunotherapy

  2023cites this paper
• FAT4 loss initiates hepatocarcinogenesis through the switching of canonical to noncanonical WNT signaling pathways

  2023cites this paper
• The cytological features of effusions with mesothelioma in situ: A report of 9 cases

  2023cites this paper
• Cholecystokinin Receptor Antagonist Induces Pancreatic Stellate Cell Plasticity Rendering the Tumor Microenvironment Less Oncogenic

  2023cites this paper
• Development of a novel copper metabolism-related risk model to predict prognosis and tumor microenvironment of patients with stomach adenocarcinoma

  2023cites this paper
• A signature based on neutrophil extracellular trap‐related genes for the assessment of prognosis, immunoinfiltration, mutation and therapeutic response in hepatocellular carcinoma

  2023cites this paper
• RT-PCR demonstrates superior sensitivity and specificity in detecting the five neuroblastoma genes compared to the flow cytometry method for measurable residual disease

  2023cites this paper
• THE CONDITION OF T- AND B-CELLS SPECIFIC IMMUNITY IN DOGS WITH BREAST TUMORS

  2023cites this paper
• Developing a Multitargeted Anticancer Palladium(II) Agent Based on the His-242 Residue in the IIA Subdomain of Human Serum Albumin.

  2023cites this paper
• Inhibition of Bone Marrow-Mesenchymal Stem Cell-Induced Carbonic Anhydrase IX Potentiates Chemotherapy Efficacy in Triple-Negative Breast Cancer Cells

  2023cites this paper
• Reactive oxygen species and its manipulation strategies in cancer treatment.

  2023cites this paper
• Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications

  2023cites this paper
• Redox-Sensitive Delivery of Doxorubicin from Nanoparticles of Poly(ethylene glycol)-Chitosan Copolymer for Treatment of Drug-Resistant Oral Cancer Cells

  2023cites this paper
• Bone mesenchymal stem cells promote gastric cancer progression through TGF-β1/Smad2 positive feedback loop.

  2023cites this paper
• N6-methyladenosine related gene expression signatures for predicting the overall survival and immune responses of patients with colorectal cancer

  2023influential citation
• Synergistic cancer immunotherapy utilizing programmed Salmonella typhimurium secreting heterologous flagellin B conjugated to interleukin-15 proteins.

  2023cites this paper
• Reprogramming of cancer-associated fibroblasts combined with immune checkpoint inhibitors: A potential therapeutic strategy for cancers.

  2023cites this paper
• Correlations between Circulating and Tumor-Infiltrating CD4+ T Cell Subsets with Immune Checkpoints in Colorectal Cancer

  2022cites this paper
• Single-Cell Sequencing and Its Applications in Liver Cancer

  2022cites this paper
• Multi-Omics Profiling of the Tumor Microenvironment.

  2022cites this paper
• Minimally Invasive Preclinical Monitoring of the Peritoneal Cavity Tumor Microenvironment

  2022cites this paper
• Analysis of m6A Methylation Modification Patterns and Tumor Immune Microenvironment in Breast Cancer

  2022cites this paper
• Acquired resistance for immune checkpoint inhibitors in cancer immunotherapy: challenges and prospects

  2022cites this paper
• Apoptosis-Related Signature Predicts Prognosis and Immune Microenvironment Infiltration in Lung Adenocarcinoma

  2022cites this paper
• Tumor-Associated Lymphatics Upregulate MHC-II to Suppress Tumor-Infiltrating Lymphocytes

  2022cites this paper
• Transmembrane serine protease 2 cleaves nidogen 1 and inhibits extrahepatic liver cancer cell migration and invasion

  2022cites this paper
• Construction of m6A-based prognosis signature and prediction for immune and anti-angiogenic response

  2022cites this paper
• CD36 and Its Role in Regulating the Tumor Microenvironment

  2022cites this paper
• The Radiobiology of TGFβ.

  2022cites this paper
• Identification and Validation of an Immune Evasion Molecular Subgroup of Patients With Colon Cancer for Implications of Immunotherapy

  2022cites this paper
• IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells

  2022cites this paper
• Immunotherapies of retinoblastoma: Effective methods for preserving vision in the future

  2022cites this paper
• Differential immune landscapes in appendicular versus axial skeleton

  2022cites this paper
• Metabolism reprogramming signature associated with stromal cells abundance in tumor microenvironment improve prognostic risk classification for gastric cancer

  2022cites this paper
• Wentilactone A Reverses the NF-κB/ECM1 Signaling-Induced Cisplatin Resistance through Inhibition of IKK/IκB in Ovarian Cancer Cells

  2022cites this paper
• N6-Methylandenosine-Related Gene Expression Signatures for Predicting the Overall Survival and Immune Responses of Patients With Colorectal Cancer

  2022influential citation
• Immunometabolism in bladder cancer microenvironment.

  2022cites this paper
• An integrative microenvironment approach for laryngeal carcinoma: the role of immune/methylation/autophagy signatures on disease clinical prognosis and single-cell genotypes

  2021cites this paper
• A new KSRP-binding compound suppresses distant metastasis of colorectal cancer by targeting the oncogenic KITENIN complex

  2021cites this paper
• An Immunometabolic Shift Modulates Cytotoxic Lymphocyte Activation During Melanoma Progression in TRPA1 Channel Null Mice

  2021cites this paper
• Therapeutic Targets and Tumor Microenvironment in Colorectal Cancer

  2021cites this paper
• Prognostic significance and immune infiltration of microenvironment-related signatures in pancreatic cancer

  2021cites this paper
• Immunomodulatory potential of chitosan-based materials for cancer therapy: a systematic review of in vitro, in vivo and clinical studies.

  2021cites this paper
• Exosomes secreted by chemoresistant ovarian cancer cells promote angiogenesis

  2021cites this paper
• Integrating m6A Regulators-Mediated Methylation Modification Models and Tumor Immune Microenvironment Characterization in Caucasian and Chinese Low-Grade Gliomas

  2021cites this paper
• m6A-Mediated Tumor Invasion and Methylation Modification in Breast Cancer Microenvironment

  2021cites this paper
• Machine learning and deep learning methods that use omics data for metastasis prediction

  2021cites this paper
• Cholecystokinin Receptor Antagonist Improves Efficacy of Chemotherapy in Murine Models of Pancreatic Cancer by Altering the Tumor Microenvironment

  2021cites this paper
• Overcoming Therapy Resistance and Relapse in TNBC: Emerging Technologies to Target Breast Cancer-Associated Fibroblasts

  2021cites this paper
• S100A8/A9 mediate the reprograming of normal mammary epithelial cells induced by dynamic cell–cell interactions with adjacent breast cancer cells

  2021cites this paper
• RNA N6-Methyladenosine Patterns in Hepatocellular Carcinoma Reveal a Distinct Immune Infiltration Landscape and Clinical Significance

  2021cites this paper
• Label-free multimodal nonlinear optical microscopy for biomedical applications

  2021cites this paper
• Combinatorial therapy in tumor microenvironment: Where do we stand?

  2021cites this paper
• Downregulation of tumor‐derived exosomal miR-34c induces cancer‐associated fibroblast activation to promote cholangiocarcinoma progress

  2021cites this paper
• Targeting the mu-Opioid Receptor for Cancer Treatment

  2021cites this paper
• Immunogenomic characterization in gastric cancer identifies microenvironmental and immunotherapeutically relevant gene signatures

  2021cites this paper
• ADAM28 from both endothelium and gastric cancer cleaves von Willebrand Factor to eliminate von Willebrand Factor-induced apoptosis of gastric cancer cells.

  2021cites this paper
• Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer

  2021cites this paper
• Integrated analyses of m1A regulator-mediated modification patterns in tumor microenvironment-infiltrating immune cells in colon cancer

  2021cites this paper
• Photodynamic Therapy and the Biophysics of the Tumor Microenvironment

  2020cites this paper
• The prognostic value of the ratio of neutrophils to lymphocytes before and after intensity modulated radiotherapy for patients with nasopharyngeal carcinoma

  2020influential citation
• Microenvironment in Cardiac Tumor Development: What Lies Beyond the Event Horizon?

  2020cites this paper
• Sphingosine-1-Phosphate in the Tumor Microenvironment: A Signaling Hub Regulating Cancer Hallmarks

  2020cites this paper
• Pancreatic cancer-derived small extracellular vesical Ezrin regulates macrophage polarization and promotes metastasis.

  2020cites this paper
• Lysophosphatidic Acid-induced EGFR Transactivation Promotes Gastric Cancer DNA Replication Through Up-Regulation of Geminin

  2020cites this paper
• Combinatorial Epigenetic and Immunotherapy in Breast Cancer Management: A Literature Review

  2020cites this paper
• m5C Regulator-Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration Characterization in Papillary Thyroid Carcinoma

  2020cites this paper
• m5C regulator-mediated methylation modi�cation patterns and tumor microenvironment in�ltration characterization in papillary thyroid carcinoma

  2020cites this paper
• A nomogram to predict short-term outcome of radiotherapy or chemoradiotherapy based on pre/post-treatment inflammatory biomarkers and their dynamic changes in esophageal squamous cell carcinoma.

  2020cites this paper
• Tumor Microenvironment Sensitive Nanocarriers for Bioimaging and Therapeutics

  2020cites this paper
• Immunohistochemical detection of cancer-associated fibroblasts in gastrointestinal cancer as a potential prognostic biomarker of survival: meta-analysis

  2020cites this paper
• Piceatannol, a Natural Analog of Resveratrol, Exerts Anti-angiogenic Efficiencies by Blockage of Vascular Endothelial Growth Factor Binding to Its Receptor

  2020cites this paper
• The unique immune microenvironment of liver metastases: challenges and opportunities.

  2020cites this paper
• Radiation Potentiates Monocyte Infiltration into Tumors by Ninjurin1 Expression in Endothelial Cells

  2020cites this paper
• Arachidonate 12-lipoxygenase and 12-hydroxyeicosatetraenoic acid contribute to stromal aging-induced progression of pancreatic cancer

  2020cites this paper
• Up-Regulation of Activating Transcription Factor 3 in Human Fibroblasts Inhibits Melanoma Cell Growth and Migration Through a Paracrine Pathway

  2020cites this paper
• Sphingosine Kinase 1 is Associated With Immune Cell-Related Gene Expressions in Human Breast Cancer.

  2020cites this paper
• Primary tumors release ITGBL1-rich extracellular vesicles to promote distal metastatic tumor growth through fibroblast-niche formation

  2020cites this paper
• Clinical relevance of the comparative expression of immune checkpoint markers with the clinicopathological findings in patients with primary and chemoreduced retinoblastoma

  2020cites this paper
• m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer

  2020cites this paper
• Human serum albumin-based dual-agent delivery systems for combination therapy: acting against cancer cells and inhibiting neovascularization in the tumor microenvironment.

  2020cites this paper